

## University of Groningen

### Correction

de Heer, E C; Zois, C E; Bridges, E; van der Vegt, B; Sheldon, H; Veldman, W A; Zwager, M C; van der Sluis, T; Haider, S; Morita, T

*Published in:*

Journal of experimental & clinical cancer research

*DOI:*

[10.1186/s13046-023-02800-3](https://doi.org/10.1186/s13046-023-02800-3)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2023

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

de Heer, E. C., Zois, C. E., Bridges, E., van der Vegt, B., Sheldon, H., Veldman, W. A., Zwager, M. C., van der Sluis, T., Haider, S., Morita, T., Baba, O., Schröder, C. P., de Jong, S., Harris, A. L., & Jalving, M. (2023). Correction: Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer. *Journal of experimental & clinical cancer research*, 42, Article 220. <https://doi.org/10.1186/s13046-023-02800-3>

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

CORRECTION

Open Access



# Correction: Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer

E. C. de Heer<sup>1†</sup>, C. E. Zois<sup>2,3,4\*\*</sup>, E. Bridges<sup>2†</sup>, B. van der Vegt<sup>5</sup>, H. Sheldon<sup>2</sup>, W. A. Veldman<sup>1</sup>, M. C. Zwager<sup>5</sup>, T. van der Sluis<sup>5</sup>, S. Haider<sup>6</sup>, T. Morita<sup>7</sup>, O. Baba<sup>7</sup>, C. P. Schröder<sup>1,8</sup>, S. de Jong<sup>1</sup>, A. L. Harris<sup>2</sup> and M. Jalving<sup>1\*</sup>

**Correction:** *J Exp Clin Cancer Res* 42, 143 (2023)  
<https://doi.org/10.1186/s13046-023-02715-z>

Following publication of the original article [1], an error was identified in Additional File 8: Fig. 6c. HCC1806 should have been U87MG. The correct Additional File 8: Fig. 6c caption should be:

(c) Well confluency of U87MG-shCtrl and -shGYS1 cells treated with different concentrations of GTPP,

cultured in 5.6 mM glucose complete DMEM, was measured by Incucyte every 3 h.

The correction does not affect the overall Conclusion of the article. The original article has been corrected.

Published online: 28 August 2023

<sup>†</sup>E.C. de Heer, C.E. Zois, E. Bridges contributed equally to this work.

The online version of the original article can be found at <https://doi.org/10.1186/s13046-023-02715-z>.

\*Correspondence:

C. E. Zois  
christos.zois@oncology.ox.ac.uk

M. Jalving  
m.jalving@umcg.nl

<sup>1</sup>Department of Medical Oncology, University of Groningen, University Medical Center Groningen, PO Box 30.001, Groningen 9700 RB, The Netherlands

<sup>2</sup>Department of Oncology, Weatherall Institute of Molecular Medicine, Hypoxia and Angiogenesis Group, Cancer Research UK Molecular Oncology Laboratories, University of Oxford, Oxford OX3 9DS, UK

<sup>3</sup>Department of Radiotherapy and Oncology, School of Health, Democritus University of Thrace, Alexandroupolis, Greece

<sup>4</sup>Department of Oncology, MRC Weatherall Institute of Molecular Medicine, Molecular Oncology Laboratories, John Radcliffe Hospital, Oxford University, Oxford OX3 9DS, UK

<sup>5</sup>Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

<sup>6</sup>The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK

<sup>7</sup>Tokushima University Graduate School, 3-18-15, Kuramoto-Cho, Tokushima 770-8504, Japan

<sup>8</sup>Department of Medical Oncology, Antoni Van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands

## References

1. de Heer EC, Zois CE, Bridges E, et al. Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer. *J Exp Clin Cancer Res*. 2023;42:143. <https://doi.org/10.1186/s13046-023-02715-z>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

